As per MRFR analysis, the US Pleurisy Market Size was estimated at 363.3 (USD Million) in 2023. The US Pleurisy Market Industry is expected to grow from 384.3(USD Million) in 2024 to 829.55 (USD Million) by 2035. The US Pleurisy Market CAGR (growth rate) is expected to be around 7.246% during the forecast period (2025 - 2035).
The US Pleurisy Market is witnessing significant trends shaped by various factors. One of the key market drivers is the rising incidence of respiratory diseases, which has increased the awareness surrounding pleurisy as a condition. As healthcare providers focus on improving diagnosis and treatment options for respiratory ailments, the demand for effective pleurisy therapies and diagnostic tools has seen a considerable rise. The aging population in the US also contributes to this trend, as older adults are more susceptible to pleuritic conditions.
Opportunities to be explored include the development of innovative therapeutic solutions and diagnostics. Advances in medical technology, such as image-guided interventions and minimally invasive surgical procedures, present an avenue for healthcare companies to introduce new treatment options. Moreover, the increasing emphasis on personalized medicine offers a chance to tailor pleurisy treatments based on individual patient profiles, potentially leading to better outcomes and improved patient satisfaction.
Recent trends demonstrate a shift towards comprehensive patient care that includes patient education and management programs. There is a growing focus on multidisciplinary approaches to treating pleurisy, with healthcare providers collaborating to create integrated care pathways. This trend aims to enhance patient understanding of their condition, foster better communication between patients and providers, and ultimately elevate the standards of care in the US.
The regulatory environment is also evolving, with increased support for research and development in respiratory care from governmental agencies. This regulatory support not only encourages innovation but also enhances the overall quality of pleurisy treatment, thus reinforcing the importance of ongoing medical research in this area.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of respiratory diseases in the United States is a significant driver for the US Pleurisy Market Industry. According to data from the Centers for Disease Control and Prevention (CDC), chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), affect over 30 million people in the US. With rising pollution levels and increased exposure to environmental allergens, the number of patients suffering from pleurisy conditions is also expected to rise, enhancing the demand for medical interventions and therapies.
The projected growth in respiratory disease cases creates a pertinent market opportunity, prompting healthcare companies to develop focused treatment solutions. Consequently, pharmaceutical firms like Pfizer and GlaxoSmithKline are likely to invest in Research and Development for pleurisy-related treatments, given the projected increase in patients and their associated healthcare needs.
Technological advancements in diagnostic methods and treatment options are fueling growth in the US Pleurisy Market Industry. Innovations such as computerized tomography (CT) scans and ultrasound-guided pleural procedures have made diagnosing and managing pleurisy significantly more effective and precise. For instance, the American College of Chest Physicians highlights that enhanced imaging techniques have increased the accuracy of diagnosing pleural effusions.
The introduction of minimally invasive procedures for fluid drainage and the growing adoption of telemedicine for patient management represent crucial trends. As technology continues to evolve, healthcare facilities in the US are likely to incorporate these advanced solutions, leading to improved patient outcomes and contributing to market growth.
The rising investment in healthcare infrastructure in the United States is a vital factor driving the US Pleurisy Market Industry. With policy shifts and increased funding directed towards healthcare facilities, particularly post-COVID-19, there is an expanded focus on improving patient care standards. The American Hospital Association reports that hospitals are expected to receive substantial federal aid and grants, which will enable them to purchase advanced medical technologies and hire specialized staff for managing conditions like pleurisy.
This revitalization of healthcare infrastructure, coupled with an increase in health insurance coverage, is likely to encourage early diagnosis and treatment, which can enhance market prospects in the pleurisy segment.
The US Pleurisy Market exhibits substantial diversity when it comes to its Type segmentation, consisting of Acute Pleurisy, Chronic Pleurisy, and Recurrent Pleurisy. Acute Pleurisy is often characterized by sudden onset and is frequently caused by infections, injury, or other related conditions, making it an essential focal point for healthcare providers, especially in emergency settings across the US. Chronic Pleurisy differs in that it persists for an extended timeframe, commonly resulting from underlying health issues like autoimmune diseases or persistent infections, thus presenting unique challenges for long-term management and treatment strategies.
This segment demands a comprehensive approach, requiring both immediate and ongoing healthcare interventions to improve patient outcomes over time. Furthermore, the Recurrent Pleurisy category captures attention as it relates to patients experiencing multiple episodes, which may indicate more severe underlying health complications, thus necessitating additional diagnostic assessments and tailored treatment plans. The interplay between these types denotes significant implications on the overall US Pleurisy Market statistics, illustrating a complex and varied landscape of treatment needs, patient demographics, and healthcare resource allocation.
The presence of these three types sheds light on the broader public health considerations and varying levels of clinical management required, presenting opportunities for innovation in therapeutic options, patient education, and awareness campaigns in the US. Market growth in this area is guided by an increase in the rates of infections and other underlying conditions, alongside an aging population that is more prone to respiratory diseases. Consequently, understanding the unique characteristics and demands associated with each type of Pleurisy not only informs clinical practice but also assists in strategic decision-making within the healthcare industry to better serve the evolving needs of patients across the United States.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Pleurisy Market focuses significantly on the Diagnosis Method segment, which is essential for accurate identification and treatment of this respiratory condition. This segment primarily encompasses Physical Examination, Imaging Tests, and Laboratory Tests, each playing a vital role in the diagnostic process. Physical Examination is often the first step, where healthcare professionals assess patient symptoms and respiratory function, aiding in immediate evaluations. Imaging Tests, such as X-rays and CT scans, are critical for visualizing pleural inflammation and distinguishing pleurisy from similar conditions, thus ensuring appropriate clinical decisions.
Laboratory Tests, which include pleural fluid analysis and blood tests, are fundamental for confirming diagnoses and determining underlying causes. The increasing prevalence of respiratory diseases and the growing demand for precise diagnostic tools drive the importance of these methods within the US Pleurisy Market. Furthermore, advancements in imaging technologies and laboratory techniques continue to enhance diagnostic accuracy and efficiency, presenting opportunities for market growth. Overall, the robust approach to Diagnosis Method underlines its significance in managing pleurisy effectively, supporting better patient outcomes and recovery rates.
The Treatment Type segment of the US Pleurisy Market is critical in addressing the needs of patients suffering from this condition, which involves inflammation of the pleura surrounding the lungs. This segment can be divided into key areas such as Medication, Surgical Procedures, and Therapeutic Procedures. Medication plays a significant role as it often serves as the first line of treatment, focusing on pain relief and reducing inflammation. Surgical Procedures may be required in severe cases, showcasing their importance in managing complications or underlying conditions.
Therapeutic Procedures are also vital as they help in fluid removal and alleviation of symptoms, which is crucial for patient recovery. As the US population ages and related respiratory issues become more prevalent, the demand for effective treatment options in the US Pleurisy Market is anticipated to rise. Furthermore, advancements in medical technologies and increasing awareness among healthcare providers contribute to the growth of this segment, presenting a significant opportunity for innovation and improvement in patient outcomes in this continuously evolving industry.
The End User segment of the US Pleurisy Market exhibits diverse applications that cater to various healthcare settings, including hospitals, clinics, and home care. Hospitals play a critical role in the treatment and management of pleurisy, often serving as the primary facility where acute cases are diagnosed and treated, as they are equipped with advanced technology and specialist healthcare providers. Clinics contribute significantly by offering outpatient services, enhancing access to care for less severe cases of pleurisy, allowing for timely intervention and management.
The home care sector is gaining prominence, reflecting a shift towards patient-centered care wherein individuals prefer recovery in familiar environments; this approach improves comfort and potentially leads to better patient outcomes. With heightened awareness and a growing elderly population in the US, the demand across these End User segments is likely to increase, driven by several factors, including advancements in healthcare technologies and a focus on effective pain management solutions. This diversification within the End User segment not only enhances the overall accessibility of care related to pleurisy but also provides significant opportunities for growth within the US Pleurisy Market.
Overall, the segmentation underscores the importance of tailored healthcare delivery across various platforms to address the unique needs of pleurisy patients effectively.
The US Pleurisy Market demonstrates a complex mix of competitive dynamics, shaped by various stakeholders including pharmaceutical companies, healthcare providers, and regulatory entities. The disease itself, characterized by inflammation of the pleura, has led to an increasing demand for effective therapeutic solutions. Key players in this market continuously innovate and strive to enhance their product portfolios while also focusing on research and development.
Competition is not solely based on product efficacy but also on pricing strategies, distribution capabilities, and market accessibility. The involvement of regulatory agencies in approving medical treatments adds another layer of complexity, influencing the market’s competitive landscape. Therefore, the competitive insights into this market draw their significance from understanding how various companies navigate regulatory challenges, innovate therapeutics, and the ways they differentiate themselves from rivals.
Bristol Myers Squibb holds a notable position in the US Pleurisy Market with a commitment to research that continually drives the development of specialized treatments aimed at alleviating symptoms associated with pleurisy. The company is noted for its robust portfolio that includes therapies which improve patient outcomes and their quality of life.
Bristol Myers Squibb has established strong relationships with healthcare professionals, enhancing its market presence and credibility among stakeholders. Their strength also lies in extensive clinical trials which not only facilitate product approval but also garner trust among patients and providers seeking effective treatment options. With a solid foundation in immunology and oncology, their strategies emphasize innovative approaches to medical therapies relevant to pleurisy, enabling them to maintain a competitive edge.
AstraZeneca is an influential player in the US Pleurisy Market, known for its active involvement in providing treatment options for respiratory diseases. The company’s product offerings, particularly focus on therapies aimed at managing inflammation linked with pleurisy, showcases its responsiveness to patient needs. AstraZeneca has built a commendable market presence through strategic partnerships and collaborations that enhance its research efforts in the pleurisy segment.
Strengths of the company include a robust pipeline of products that leverage both small molecules and biologics, providing a comprehensive approach to treatment. Furthermore, AstraZeneca's commitment to accelerating innovation through mergers and acquisitions showcases its ambition to expand its capabilities in addressing pleurisy and related conditions effectively. This strategic direction not only strengthens their market offering but also reinforces their leadership role in the evolving landscape of treatments available for pleurisy in the United States.
In recent months, the US Pleurisy Market has seen substantial developments, especially with companies like Bristol Myers Squibb, AstraZeneca, and Merck making strides in treatment advancements. The market has been impacted by increased investment in Research and Development (R&D) focused on pleural diseases, with Eli Lilly and Novartis actively expanding their portfolios. Notably, in October 2023, Merck announced promising trial results for a new drug aimed at pleurisy, raising anticipation among stakeholders. In terms of mergers and acquisitions, there has been heightened interest in strategic partnerships, although no significant transactions have been reported recently among the key companies, including Regeneron Pharmaceuticals and Pfizer.
The growth of the market valuation for companies like Roche and AbbVie has been substantial over the past two years, driven by an improved understanding of pleural diseases and enhanced healthcare policies that effectively support patient care. Traditional therapies are also witnessing improvements, supporting major industry players as they adapt their strategies to market demands. Additionally, the commitment from the FDA to expedite approvals for new therapeutics has contributed to a more dynamic marketplace for pleurisy treatments in the US.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 363.3(USD Million) |
| MARKET SIZE 2024 | 384.3(USD Million) |
| MARKET SIZE 2035 | 829.55(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.246% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Bristol Myers Squibb, AstraZeneca, Novartis, Merck, Eli Lilly, Celgene, Regeneron Pharmaceuticals, Pfizer, Amgen, Roche, AbbVie, Sanofi, Johnson and Johnson, GSK, Vertex Pharmaceuticals |
| SEGMENTS COVERED | Type, Diagnosis Method, Treatment Type, End User |
| KEY MARKET OPPORTUNITIES | Growing awareness of pleurisy treatments, Increased investment in R&D, Expansion of telemedicine services, Rising demand for personalized medicine, Advancements in diagnostic technologies |
| KEY MARKET DYNAMICS | increasing prevalence of pleurisy, advancements in diagnostic technologies, growing awareness and education, expanding treatment options, rising healthcare expenditure |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Pleurisy Market is expected to be valued at approximately 384.3 million USD in 2024.
By 2035, the US Pleurisy Market is anticipated to reach a value of around 829.55 million USD.
The market is expected to experience a CAGR of 7.246% from 2025 to 2035.
The market is segmented into Acute Pleurisy, Chronic Pleurisy, and Recurrent Pleurisy.
Acute Pleurisy is projected to be valued at approximately 150.0 million USD in 2024.
By 2035, Chronic Pleurisy is expected to have a market value of around 250.0 million USD.
Key players include Bristol Myers Squibb, AstraZeneca, Novartis, Merck, and Pfizer.
In 2024, the market size for Recurrent Pleurisy is expected to be about 114.3 million USD.
Growing incidence of respiratory diseases and advancements in treatment options are key growth drivers.
Emerging treatment options and increased awareness of pleurisy will significantly boost market growth until 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
